Table 1 Autoantibody prevalence in a cohort of adult Italian patients with PM/DM.
| Â | Total (n = 58) | DM (n = 27) | PM (n = 25) | Overlap syndrome (n = 6) |
|---|---|---|---|---|
Myositis-related antibodies | Â | Â | Â | Â |
Anti-MJ | 17% (10) | 30% (8)1 | 8% (2)1 | 0 |
Anti-Jo-1 | 10% (6) | 02 | 24% (6)2 | 0 |
Anti-p155/140 | 5% (3) | 7% (2) | 0 | 17% (1) (DM-SLE-Sjögren's) |
Anti-SRP | 5% (3) | 0 | 8% (2) | 17% (1) (PM-RA) |
Anti-EJ | 3% (2) | 4% (1) | 4% (1) | 0 |
Anti-Mi-2 | 2% (1) | 5% (1) | 0 | 0 |
Anti-OJ | 2% (1) | 0 | 4% (1) | 0 |
Anti-PM/Scl | 10%(6) | 11% (3) | 8% (2) | 17% (1) (DM-SSc) |
Anti-U1RNP | 7% (4) | 4% (1) | 4% (1) | 33% (2) (DM-SSc; PM-SLE) |
Anti-Ro | 3% (2) | 0 | 8% (2) | 0 |
Anti-Su | 3% (2) | 4% (1) | 0 | 17% (1) (PM-SSc) |
Negative/unknown | 38% (22) | 41% (11) | 40% (10) | 17% (1) (PM-SSc) |